Objective: To investigate the interactions between selected phenolic compounds (hesperidin, naringin, neohesperidin, kaempferol, apigenin, hesperetin, and nobiletin) and syncytin-2 protein, evaluating their potential as novel therapeutic agents for glioblastoma and lung cancer treatment.
Methods: Molecular docking simulations were employed to analyze phenolic compound-syncytin-2 protein interactions. Comprehensive in silico ADMET analyses were conducted to assess pharmacokinetic properties and toxicity profiles of the compounds.
Results: Hesperidin and neohesperidin exhibited the highest affinity to syncytin-2, with binding affinities of -10.5 kcal/mol and -10.0 kcal/mol, respectively. Molecular-level analyses demonstrated that hesperidin forms critical hydrogen bonds and hydrophobic interactions with Isoleucine 371, Alanine 372, and Leucine 309 amino acid residues. ADMET analyses revealed that these two compounds exhibit low toxicity potential and optimal pharmacokinetic profiles.
Conclusion: This research provides evidence that phenolic compounds may serve as inhibitors of syncytin-2 in the treatment of glioblastoma and lung cancer. The identified molecular interactions and promising ADMET profiles support the need for further investigation of these compounds. Future studies should focus on optimizing phenolic compound-based inhibitors, conducting preclinical and clinical evaluations, and assessing their potential therapeutic effects within the tumor microenvironment.
Glioblastoma multiforme lung cancer syncytin-2 phenolic compounds molecular docking ADMET analysis
Objective: To investigate the interactions between selected phenolic compounds (hesperidin, naringin, neohesperidin, kaempferol, apigenin, hesperetin, and nobiletin) and syncytin-2 protein, evaluating their potential as novel therapeutic agents for glioblastoma and lung cancer treatment.
Methods: Molecular docking simulations were employed to analyze phenolic compound-syncytin-2 protein interactions. Comprehensive in silico ADMET analyses were conducted to assess pharmacokinetic properties and toxicity profiles of the compounds.
Results: Hesperidin and neohesperidin exhibited the highest affinity to syncytin-2, with binding affinities of -10.5 kcal/mol and -10.0 kcal/mol, respectively. Molecular-level analyses demonstrated that hesperidin forms critical hydrogen bonds and hydrophobic interactions with Isoleucine 371, Alanine 372, and Leucine 309 amino acid residues. ADMET analyses revealed that these two compounds exhibit low toxicity potential and optimal pharmacokinetic profiles.
Conclusion: This research provides evidence that phenolic compounds may serve as inhibitors of syncytin-2 in the treatment of glioblastoma and lung cancer. The identified molecular interactions and promising ADMET profiles support the need for further investigation of these compounds. Future studies should focus on optimizing phenolic compound-based inhibitors, conducting preclinical and clinical evaluations, and assessing their potential therapeutic effects within the tumor microenvironment.
Glioblastoma multiforme lung cancer syncytin-2 phenolic compounds molecular docking ADMET analysis
Primary Language | English |
---|---|
Subjects | Bioinformatics and Computational Biology (Other) |
Journal Section | Original Article / Medical Sciences |
Authors | |
Publication Date | March 21, 2025 |
Submission Date | December 31, 2024 |
Acceptance Date | February 13, 2025 |
Published in Issue | Year 2025 Volume: 11 Issue: 1 |